Business Description
Mirati Therapeutics Inc
NAICS : 325412
SIC : 2834
Description
Mirati Therapeutics Inc is a clinical-stage oncology company developing novel therapeutics to address the genetic and immunological promoters of cancer. It operates in a single geographical segment being the United States.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 23.57 | |||||
| Equity-to-Asset | 0.87 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | -0.08 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 10.75 | |||||
| Beneish M-Score | 0.56 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 49.3 | |||||
| 3-Year EBITDA Growth Rate | -49.2 | |||||
| 3-Year EPS without NRI Growth Rate | -52.1 | |||||
| 3-Year FCF Growth Rate | -50.1 | |||||
| 3-Year Book Growth Rate | 59.7 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 27.21 | |||||
| 9-Day RSI | 30.9 | |||||
| 14-Day RSI | 36.22 | |||||
| 6-1 Month Momentum % | -8.66 | |||||
| 12-1 Month Momentum % | -52.24 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.1 | |||||
| Quick Ratio | 10.1 | |||||
| Cash Ratio | 9.91 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -19.4 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -816.24 | |||||
| Net Margin % | -826.41 | |||||
| ROE % | -54.09 | |||||
| ROA % | -46.81 | |||||
| ROIC % | -575.93 | |||||
| ROC (Joel Greenblatt) % | -1204.9 | |||||
| ROCE % | -51.37 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 45.13 | |||||
| PB Ratio | 3.39 | |||||
| Price-to-Tangible-Book | 3.4 | |||||
| EV-to-EBIT | -4.15 | |||||
| EV-to-EBITDA | -4.16 | |||||
| EV-to-Revenue | 33.88 | |||||
| EV-to-Forward-Revenue | 75.38 | |||||
| EV-to-FCF | -5.38 | |||||
| Price-to-Net-Current-Asset-Value | 3.65 | |||||
| Price-to-Net-Cash | 3.73 | |||||
| Earnings Yield (Greenblatt) % | -24.07 |
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MRTX
Peter Lynch Chart
Performance
Dividend
Annualized Return %
Total Annual Return %
Executives
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 78.163 | ||
| EPS (TTM) ($) | -11.85 | ||
| Beta | 0.34 | ||
| Volatility % | 102.78 | ||
| 14-Day RSI | 36.22 | ||
| 14-Day ATR ($) | 4.077717 | ||
| 20-Day SMA ($) | 75.368 | ||
| 12-1 Month Momentum % | -52.24 | ||
| 52-Week Range ($) | 32.96 - 195.99 | ||
| Shares Outstanding (Mil) | 55.61 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mirati Therapeutics Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mirati Therapeutics Inc Analysis
Share your researchHeadlines
See More
No news.